Top Markets
Coin of the day
Novogene Co., Ltd. Novogene Co., Ltd.

Novogene Co., Ltd.

688315
株式のランク #9857
Novogene Co., Ltd. is a global provider of comprehensive genomic services and... Novogene Co., Ltd. is a global provider of comprehensive genomic services and advanced solutions. Its offerings span a wide array of genomic applications, including human, animal, plant, and microbial genome sequencing, alongside gene regulation and single-cell sequencing technologies. The company also specializes in cancer genomic profiling, whole exome sequencing (including clinical-grade versions), and FFPE RNA sequencing. Furthermore, Novogene develops proprietary tools such as NovoFocus, a next-generation sequencing (NGS)-based companion diagnostic for PARP inhibitor treatments, and NovoNeoantigen, a bioinformatics pipeline that identifies cancer neoantigens by analyzing whole exome and whole transcriptome sequencing data from matched tumor and normal samples. In a strategic collaboration, Novogene partners with Hummingbird Bioscience Pte. Ltd. to aid in the advancement of HMBD-001. This investigational anti-HER3 antibody is being assessed for its potential to treat diverse cancer types, notably those driven by NRG1-fusion. Established in 2011, Novogene Co., Ltd. operates from its headquarters in Beijing, China.
株価
$2.25
最終同期: 2026-08-28
時価総額
$936.66M
変化(1日)
-3.18%
変化(1年)
3.07%
CN
取引 Novogene Co., Ltd. (688315)

カテゴリー

Novogene Co., Ltd.(688315)の収益
Aug 2026 時点の収益 TTM: 0
Novogene Co., Ltd. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Novogene Co., Ltd. の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差
$12.62B -
US
$6.02B -
NL
$15.74B -
AU
$2.23B -
US
- -
CH